Drug Trial Radar · NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Dec 1, 2026
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Conditions
- B-cell Mediated Autoimmune Disorders
Interventions
Azercabtagene zapreleucel (azer-cel)Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: From Day 0 to Day 28
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
La Jolla, California · Recruiting
TG Therapeutics Investigational Trial Site
Ann Arbor, Michigan · Recruiting
TG Therapeutics Investigational Trial Site
Omaha, Nebraska · Recruiting
TG Therapeutics Investigational Trial Site
New York, New York · Recruiting
TG Therapeutics Investigational Trial Site
Rochester, New York · Recruiting
TG Therapeutics Investigational Trial Site
Cleveland, Ohio · Recruiting
TG Therapeutics Investigational Trial Site
Columbus, Ohio · Recruiting
TG Therapeutics Investigational Trial Site
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.